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Abstract
Background: Pathogenic or regulatory effects of natural killer (NK) cells are implicated in many autoimmune
diseases, but evidence in multiple sclerosis (MS) and its murine models remains equivocal. In an effort to illuminate
this, we have here analysed expression of the prototypic NK cell marker, NCR1 (natural cytotoxicity triggering
receptor; NKp46; CD335), an activating receptor expressed by virtually all NK cells and therefore considered a pan-
marker for NK cells. The only definitive ligand of NCR1 is influenza haemagglutinin, though there are believed to
be others. In this study, we investigated whether there were differences in NCR1+ cells in the peripheral blood of
MS patients and whether NCR1+ cells are present in white matter lesions.
Results: We first investigated the expression of NCR1 on peripheral blood mononuclear cells and found no significant
difference between healthy controls and MS patients. We then investigated mRNA levels in central nervous system
(CNS) tissue from MS patients: NCR1 transcripts were increased more than 5 times in active disease lesions. However
when we performed immunohistochemical staining of this tissue, few NCR1+ NK cells were identified. Rather, the major
part of NCR1 expression was localised to astrocytes, and was considerably more pronounced in MS patients than
controls. In order to further validate de novo expression of NCR1 in astrocytes, we used an in vitro staining of the human
astrocytoma U251 cell line grown to model whether cell stress could be associated with expression of NCR1. We found
up-regulation of NCR1 expression in U251 cells at both the mRNA and protein levels.
Conclusions: The data presented here show very limited expression of NCR1+ NK cells in MS lesions, the majority
of NCR1 expression being accounted for by expression on astrocytes. This is compatible with a role of this cell-type
and NCR1 ligand/receptor interactions in the innate immune response in the CNS in MS patients. This is the first
report of NCR1 expression on astrocytes in MS tissue: it will now be important to unravel the nature of cellular
interactions and signalling mediated through innate receptor expression on astrocytes.
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Background
Natural cytotoxicity receptors
NCR1 (natural cytotoxicity triggering receptor; NKp46;
CD335) is a key receptor initiating NK cell mediated
cytolysis [1]. It is expressed on all human NK cells irre-
spective of their state of maturation and activation and
has been regarded as the prototypic, pan-NK cell marker
[2]. The direct killing of a target by NK cells is orche-
strated by activating receptors including CD16, CD80,
NCR2 (NKp44 or CD336), NCR3 (NKp30 or CD337),
NKG2D (CD314), 2B4 (CD244), the novel NKp80
(KLRF1) and the killer cell immunoglobulin-like recep-
tors-KIRs [3].
NCR1 was first identified in 1997 [4] and cloned one
year later [5]. NCR1 is a 46 kDa type I transmembrane
glycoprotein, characterised by two C2-type immunoglo-
bulin-like domains in the extracellular portion and
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hence a member of the immunoglobulin superfamily
(IgSF). NCR1 (or NKp46) shares similarities with
NKp30, while NKp44 is different and is only expressed
on activated NK cells [6]. The crystal structure of NCR1
shows structural similarities to LIR1, KIR2DL2, FcgRIIb
and other Fc receptors [7]. Upon activation, NCR1
increases cytotoxicity, Ca2+ mobilisation and cytokine
production in NK cells [4]. NCR1 is not uniformly
expressed, the surface density on NK cells varying
between individuals. In a control population, < 20%
donors display the NCRdull phenotype while most
donors express a high density of NCRs on NK cells,
NCRbright phenotype [8]. This expression difference
underpins a relationship between NCR density and NK
mediated-cytolytic activity [3]. Decreased NCR (NKp30
and NKp46) expression on NK cells in the elderly has
been reported, potentially impacting on susceptibility to
infectious, inflammatory, and neoplastic diseases [9].
Relatively little is known about NCR1 ligands. To date,
the only unequivocally identified ligands for NCR1 are
influenza haemagglutinin [1,10].
NCR1 in disease
Activating NK receptors recognise stress-induced
ligands and viral products. Following influenza virus
infection, an increased recognition and binding of NK
cells with infected cells via the NCR1 receptor is
observed [11]. It has been suggested that NCR1+ NK
cells may have a role in mediating the pathogenesis of
Crohn’s disease by producing interferon-g [12]. Further-
more, NCR1 was shown to be essential for the develop-
ment of diabetes [13]. The role of NK cells in general
and NCR1+ cells in particular in MS is unclear. The fact
that there are NK cell subsets showing varying cytokine
profiles and cytotoxicity underpins uncertainty in the
MS literature as to whether NK cells are pathogenic or
regulatory [14]. Evidence from the murine model,
experimental autoimmune encephalomyelitis (EAE) has
been used to argue both views [15,16]. Ex vivo evidence
suggests that NK cells have the capacity to lyse cultured
primary oligodendrocytes and foetal astrocytes but not
adult astrocytes, neurones or microglia via NKG2D
ligands which are expressed in the MS brain [17].
Another study has shown NK cells to be cytotoxic to
resting but not activated microglia, via NKG2D and
NKp46 [18]. Evidence from EAE suggests that NK cells
may be protective through their ability to make neuro-
trophic growth factors [19]. Evidence from humans also
suggests a protective role for NK cells in MS: ameliora-
tion of MS by treatment with interferon-b [20] and anti-
CD25 antibodies [21] or during pregnancy, correlates
with expansion of presumed regulatory NK cells [22].
Also, CD95 (Fas) positive NK cells expand during remis-
sion [23] and are proposed to kill activated T cells.
Nevertheless, studies using untreated MS patients have
mostly detected deficits in NK cells function rather than
differences in overall numbers between MS and con-
trols. For instance, a reduction of an NK cell subtype,
CD8lowCD56+CD3-CD4-, was observed in untreated,
clinical isolated demyelination syndrome (CIS) and in
relapse remitting MS (RRMS) patients, suggesting that
this decrease in CD8low NK cells is an early event in
demyelinating diseases [24]. The action of daclizumab
(anti-IL2Ra) may restore to normal levels the
CD8lowCD56+CD3-CD4- subset, this expansion correlat-
ing with decreased brain inflammation and decreased
survival of activated T cells [21]. Two broad subsets of
NK cells have been characterised, CD56bright CD16dim/
neg and CD56dim CD16bright/pos, the former being more
regulatory (or at least, cytokine secreting) and the latter
being more cytotoxic [25]. Lunemann and colleagues
found interferon-g release from the CD56bright CD16dim/
neg subset to be diminished in MS patients [26].
We here aimed to determine whether abnormal NCR1
expression could be found in MS patients and whether
NK cells are present in white matter lesions, using the
NCR1 receptor as an NK cell marker.
Materials and methods
Blood donors and PBMC preparation
Healthy controls were recruited within Imperial College
London, while MS donors were recruited during the MS
Clinic in Charing Cross, NHS Trust-Imperial College
London. We recruited 9 healthy controls, 8 RRMS naive
patients (i.e. no prior treatment received), 8 progressive
MS (PMS) and 9 interferon-b-treated RRMS patients.
Blood samples were collected in heparin tubes and pro-
cessed within five hours. All donors gave informed con-
sent previously approved by the research ethics
committee (05/MRE12/8). Peripheral blood mononuc-
lear cells (PBMCs) were isolated using Histopaque 1077
(Sigma-Aldrich, Gillingham, UK) gradients. We used
freshly separated cells for immunophenotyping experi-
ments by flow cytometry. For RNA extraction, cryopre-
served PBMCs were used and treated as described in
the following paragraphs.
Flow cytometry
Single cell analysis of PBMC was carried out using
multi-parameter flow cytometry. Mouse anti human
CD3-Allophycocyanin (APC)-H7 (clone SK7), CD16-
Fluorescein isothiocyanate (FITC) (clone B73.1), CD56-
phycoerythrin (PE)-Cy7 (clone B159), NKp46- phycoery-
thrin (PE) (Clone 9E2/NKp46) were purchased from BD
Bioscience (Becton Dickinson, Oxford, UK). Freshly iso-
lated PBMCs were blocked on ice with 10% human
serum in washing buffer (1% BSA in PBS), and subse-
quently stained with the cocktail of antibodies as
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described above for 45 min on ice, in the dark. After
incubation, cells were washed twice with washing buffer
(1% BSA in PBS) and fixed using a solution of 1% PFA
in PBS. For each donor, we included isotype controls for
CD16, CD56 and NKp46. Cell surface expression level
of NKp46 is expressed as ratio of the MFI (Mean Fluor-
escence Intensity) of NKp46 positive cells and the MFI
of matching isotype control for the same donor.
Human tissue samples
MS and control brain tissue samples were kindly
donated from the UK Multiple Sclerosis Tissue Bank
(Centre for Neuroscience, Imperial College Faculty of
Medicine, Hammersmith Campus, London, UK) and the
human brain tissue bank in Budapest (Department of
Anatomy, Semmelweis University, Budapest, Hungary).
Fully informed consent and ethical approval were
obtained for the collection and study of post-mortem
tissue following local and guidelines recently published
by the BrainNet Europe Brain Bank Consortium [27].
All post-mortem MS tissues were obtained via a UK
prospective donor scheme with full ethical approval (08/
MRE09/31). Neuropathological confirmation of the diag-
nosis of MS was carried out according to the Interna-
tional Classification of Diseases of the Nervous System
criteria http://www.ICDNS.org. Samples were taken
from 12 MS patients of which 11 were female and 1
male with ages at death ranging from 34 to 59 years
(mean = 46.6). The majority of MS cases were second-
ary progressive (SPMS) and disease duration ranged
from 2 to 36 years (mean = 16.7). The 10 control
patients, 7 females and 3 males, were free of any evi-
dence of known neurological disease, and had an aver-
age age at death of 47 (range 26-60). Further details of
control and MS cases can be found in supplementary
Tables 1 and 2 respectively (Additional file 1). Groups
were matched for gender and age at death and when
compared were not statistically different based on gen-
der (Fisher’s exact test; p = 0.2932) or age at death (t =
0.91) and showed similar homogeneity of variances for
both group (FTest = 0.33). Lesioned tissue of MS
patients was identified on serial sections by standard
immunostaining for myelin oligodendrocyte glycoprotein
(MOG) expression and by Luxol® fast blue (LFB) solu-
tion (Sigma-Aldrich Company Ltd, UK). Parkinson’s dis-
ease (PD) tissue was donated from the UK Parkinson’s
disease Tissue bank (Centre for Neuroscience, Imperial
College Faculty of Medicine, Hammersmith Campus,
London, UK). Appendix and tonsil inflamed tissue was
kindly donated from the Human Biomaterials Resource
Centre (Hammersmith Hospitals NHS Trust, Hammer-
smith Hospital, London, UK). The tonsil donor was a 19
year old female who underwent tonsillectomy due to
reactive lymphoid hyperplasia and the appendix donor
was female, 50 years, who underwent appendectomy.
Cell lines and cell culture experiments
The human U251 astrocytoma cell line was a kind gift
from Dr Amin Hajitou, (Department of Gene Therapy,
Division of Neuroscience, Imperial College London).
The cells were used in our experiments between the 3rd
and the 10th passage. For both RNA extraction and flow
cytometry, cells were plated at 0.5 × 106/well or 2 ×
106/well. For confocal microscopy, cells were plated
directly in glass bottom slides at the same cell density,
having taken into account the number of cells/cm2 in
both culture conditions. The cells were let to adhere
overnight and the following day, were divided in two
groups: one was left 24 hr in DMEM without FCS, the
other group in DMEM culture media supplemented
with FCS. After 24 hr both groups were cultured for 72
hr with DMEM with FCS. At this time point, cells were
harvested for RNA extraction or stained directly on
glass slides for confocal microscopy.
For RNA extraction, cells were washed twice in cold
PBS and the pellet frozen at -80°C. RT-PCR products
were visualised by agarose gel electrophoresis on 2%
agarose TAE gels with SYBR® Safe DNA gel stain (Invi-
trogen, Paisley, UK). HyperLadder™ II (Bioline, London,
UK) was used as the molecular weight marker. Gels
were visualised with a BioDoc-It® Imaging System
(UVP, Cambridge, UK) and LabWorks™ image capture
and analysis software. ImageJ software [28] was used to
conduct as semi-quantitative analysis of expression.
Mean voxel intensity of bands was used to determine
product expression of the reference gene and gene of
interest (GOI). GOI intensities were divided by their
respective reference gene intensities to determine final
expression of NCR1 (as a percentage).
For confocal microscopy, U251 cells were grown
directly in cell-culture pre-treated 8- well chamber slides
(LabTek™, Nunc, Thermo Fisher Scientific). At chosen
time points, the chambers were removed from the slides.
The slides were washed twice in ice-cold PBS, then fixed
with ice-cold methanol for 30 min, air-dried and stained
with NKp46 antibody or isotype control. After 45 min
incubation, slides were washed twice, then incubated
with donkey anti-mouse secondary antibody Alexa Fluor-
488 conjugated and donkey anti-rabbit secondary anti-
body Alexa Fluor-680 conjugated (Invitrogen, Paisley,
UK). After 45 min incubation the slides were washed
twice, incubated with DAPI (2.5 ng/μL final concentra-
tion from Invitrogen, Paisley, UK) for 10 min, washed
twice in PBS and once in distilled water before mounting
with fluorescent mounting medium (DAKO, Ely, UK).
The mounted slides were stored in the dark at 4°C.
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RNA extraction
Total RNA was extracted from dissected snap-frozen tis-
sue (< 100 mg) according to an optimised protocol [29]
using the RNeasy® tissue lipid mini kit (Qiagen Ltd,
Crawley, UK) according to the manufacturer’s instruc-
tions, and was stored at -80°C until further use. RNA
concentration and purity was assessed by spectrophoto-
metry (NanoDrop ND1000; NanoDrop Technologies,
Delaware, USA).
Quantitative Real Time Polymerase Chain Reaction (RT-
qPCR)
The two-step real-time reverse transcriptase quantitative
polymerase chain reaction (RT-qPCR) was performed
using the QuantiTect® reverse transcription kit and the
Brillant® II QPCR master mix with low ROX from Agi-
lent technologies (Agilent technologies UK Ltd, Edin-
burgh, UK). For cDNA synthesis, 1 μg of total RNA
from each sample was reverse transcribed according to
the manufacturer’s instructions using the QuantiTect®
reverse transcription kit with integrated removal of
genomic DNA contamination. No reverse-transcriptase
reactions (No RT) consisted of the same protocol as
above but the Quantiscript reverse transcriptase was
omitted and replaced with RNase free-water. The reac-
tions were stored at -20°C until further use. Real-time
PCR experiments were performed using the Mx3000P™
real-time PCR system with software version 4.10 (Strata-
gene, La Jolla, USA).
For each sample, 20 μl reactions were set up in dupli-
cate and in duplex, with each reaction containing 10 μl
of 2× master mix, 2 μl of 10× primetime assay (1 μl of
GOI + 1 μl of normaliser), 7 μl of RNase-free water and
1 μl template cDNA. PrimeTime™ qPCR assays were
purchased from Integrated DNA technology (Coralville,
Iowa, USA) and are listed in table 1. Reactions were car-
ried out with the following cycling protocol: 95°C for 10
min, then 45 cycles with a 3-step program (95°C for 15
s, 50°C for 30 s and 72°C for 30 s). Fluorescence data
collection was performed during the annealing step.
Control No RT reactions to test for contaminating DNA
and a negative control containing no cDNA template
were introduced in each run.
Efficiencies of the primer/probe assays were tested
individually and in duplex. Expression levels of target
genes were normalised to the levels of the novel
XPNPEP1 [X-prolyl aminopeptidase (aminopeptidase
P) 1] reference gene (unpublished data by Pascal F
Durrenberger) and calibrated utilising a standard
curve method for quantitation. Some experiments
were then duplicated using a more commonly used
normaliser; GAPDH. The calibrator was generated by
creating a pool from all the control cDNA samples.
Levels of the calibrator represented the baseline (of
one) from which all RNA expression values were cal-
culated within an experiment. The standard curve was
used to determine relative quantity expression values
for each target gene after RT-qPCR analysis of each
test specimen. Relative expression values for each tar-
get gene are expressed as a ratio of target gene
expression level to the reference gene expression level
in the same specimen.
Immunohistochemistry and immunofluorescence
Snap frozen tissue sections were fixed in 4% parafor-
maldehyde (PFA) for 10 min at 4°C and rinsed in PBS.
Sections were then permeabilised and endogenous per-
oxidase activity removed by incubation in methanol
containing 1% hydrogen peroxide for 15 min at -20°C.
After two rinses, primary antibodies (Abs) was applied
at tested or manufacturers recommended dilution at
200 μl per slide and left to incubate overnight at room
temperature (RT). All primary antibodies are listed in
Table 2. After an overnight incubation, sections were
rinsed with PBS and biotinylated secondary Abs were
applied at the following dilutions: anti rabbit at 1:200,
anti-mouse and goat at 1:100, at 200 μl per slide and
incubated for 45 mins (RT). Slides were rinsed in PBS.
Table 1 Primers and probes
GAPDH Assay ID Hs.PT.42.1164609
Probe 5’-/5HEX/TGC GGT CAC CAT CAATGA AGA GCA/3IABkFQ/-3’
Primer 1 5’-CGC AAT CAT AGG ACT AGA GAC G-3’
Primer 2 5’-GAT CCT GTATTC GGCTTC CAG-3’
NCR1 Assay ID Hs.PT.1994249
Probe 5’-/56-FAM/CGAGAGGGT/ZEN/GGGTGTGTCATACATTTC/3IABkFQ/-3’
Primer 1 5’- TCTAGACGGCAGTAGAAGGTC -3’
Primer 2 5’- CTTGCTGGATCTGGTGGTAA -3’
XPNPEP1 Assay ID Hs.PT.42.500129
Probe 5’-/5HEX/TGCGGTCACCATCAATGAAGAGCA/3IABkFQ/-3’
Primer 1 5’- CGCAATCATAGGACTAGAGACG -3’
Primer 2 5’- GATCCTGTATTCGGCTTCCAG -3’
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A complex of avidin and biotin (ABC) solution was
prepared 30 min before application. Solution A and B
were added at 5 μl, to 1 ml of 1% bovine serum albu-
min (BSA) diluted in PBS. ABC solution was applied
to slides at 200 μl per slide and incubated for 60 min
(RT). Slides were then rinsed in PBS. NovaRed™ (Vec-
tor®, Burlingame, CA, U.S.A) chromogen was prepared
to manufacturer’s instructions. Chromogen was applied
for 1-5 min depending on the primary antibody. The
reaction was stopped by rinsing in distilled water. Sec-
tions were counterstained in Mayer’s Haemalum for 2-
5 sec and rinsed for 5 min. Sections were dehydrated
and placed in 70% methylated spirit for 1 min, then
90% for 1 min, then 100% for 1 min, and again at
100% for 1 min. Slides were then placed in xylene for
4 min and mounted with a coverslip using DPX moun-
tant for microscopy and slides were left to dry before
viewing. Immunofluorescence staining was as described
for immunohistochemistry (up to the step of ABC
application) except that here the secondary Abs used
were fluorescently labelled and used at 1:500 (Invitro-
gen, Paisley, UK). After 45 min (RT) in the dark, the
sections were rinsed in PBS. Coverslips were applied
using fluorescent mounting medium (DAKO, Ely, UK)
and DAPI (Invitrogen, Paisley, UK) and the slides
dried under pressure. Reagents were purchased from
VWR (UK) unless otherwise specified.
Images were ascertained using ImagePro7 software
(MediaCybernetics, Inc, Bethesda, MD, USA) and cap-
tured with a Nikon Eclipse E1000M microscope/digital
camera system. Positive immunostaining was highlighted
by setting the gray-level detection limits to threshold
using ImageJ software [28] and the area of highlighted
immunoreactivity was obtained as percentage area of
the field scanned. Five fields per tissue section were
scanned and the mean values were used in subsequent
statistical analysis. Fluorescence images were ascertained
by fluorescent microscopy using the same Nikon Eclipse
E1000M microscope/digital camera system (QImaging)
and the Leica TCS STED confocal microscope (Leica
Microsystems GmbH, Wetzlar, Germany). Digitised
images were processed using Image ProPlus (Media
Cybernetics) and ImageJ and prepared in Adobe Photo-
shop for publication.
Statistical Analysis
Group difference was established by using the non-para-
metric Mann Whitney test or parametric t test or with a
one-way ANOVA with Bonferroni’s multiple comparison
test for multiple group comparison. Homogeneity of var-
iance was assessed using F-test. Microsoft Office Excel
2010 (Microsoft UK Headquaters, Reading, UK) and
GraphPad Prism 5.01 (GraphPad Software, La Jolla, CA)
software packages were used for statistical analysis. Data
shown as mean ± standard error of the mean (SEM) unless
stated, differences were taken as significant when p < 0.05.
Results
NCR1 receptor expression in peripheral blood
NCR1 mRNA expression levels were not significantly dif-
ferent between MS (n = 12) and control (n = 6; data not
shown). We further used flow cytometry to compare
NCR1 expression on peripheral blood NK cells of MS
patients and controls. We compared the mean NCR1
fluorescence (MFI) of gated CD56+CD3- cells from
RRMS (n = 8), treated RRMS (n = 9) and progressive MS
(n = 8) patients with controls (n = 9). A one-way
ANOVA was conducted with Bonferroni’s multiple com-
parison tests and no significant difference was found in
expression of NCR1 between groups (and nor was there
a difference in NK cell number between groups; Figure
1). There was a trend to lower NCR1 expression in MS
patients (MFI = 18.29 ± 4.734; p = 0.07) than controls
(MFI = 28.10 ± 4.2761) rising slightly after interferon-b
treatment (MFI = 21.70 ± 6.31).
NCR1 transcription in MS white matter lesions
We further investigated NCR1 by looking at NCR1 mRNA
levels in CNS white matter lesions (WML) from MS
patients. We found a significant increase (p = 0.0133) in
NCR1 mRNA levels in MS WML compared to controls
(Figure 2). Very low to undetectable levels of NCR1
mRNA were measured in post-mortem control tissue. In
MS WML, NCR1 mRNA expression varied from control
levels in some cases to very high levels, particularly in
cases with high levels of organised meningeal inflamma-
tion and associated substantial sub-pial grey matter and
focal white matter demyelinating lesions, the latter of
which contained macrophages with myelin debris
Table 2 Primary Antibodies
Antigen Target Donor Species Working Dilution Source
NCR1 Extracellular Mouse monoclonal 1:1,500 R&D Systems, Abingdon, UK
NCR1 Extracellular Goat polyclonal 1:50 R&D Systems, Abingdon, UK
NCR1 Full length Mouse monoclonal 1:100 Abcam, Cambridge, UK
NCR1 C-terminus Goat polyclonal 1:75 Santa Cruz Biotechnology®, Santa Cruz, CA, USA
GFAP Astrocytes Rabbit monoclonal 1:200 Dako UK Ltd, Ely, UK
MOG Oligodendrocytes (myelin) Mouse monoclonal 1:50 Gift of Dr S.Piddlesden, Cardiff, UK
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indicative of active lesion formation. These MS cases have
previously been characterised and reported by us [30] and
were associated with earlier disease onset, irreversible dis-
ability and death [31]. NCR1 mRNA in WML was
increased more than 5 times in response to disease activity
(Figure 2). To verify the effectiveness of macro-dissected
lesioned tissue, we verified expression levels of myelin
basic protein (MBP) and myelin-associated oligodendrocy-
tic basic protein (MOBP), which were significantly down-
regulated (data not shown).
Immunohistochemical localization of CNS NCR1
expression
Using immunohistochemical (IHC) staining we investi-
gated in situ NCR1 protein expression in the same
WML with mouse monoclonal anti-human NCR1
antibodies directed toward the extracellular domain of
NCR1. Very few NCR1+ lymphoid cells were detected in
grey and white demyelinated areas and only in the cases
showing extreme focal demyelination (2 cases) and pre-
senting more active than chronic lesions. The NCR1+
lymphoid cells detected were found in perivascular cuffs
(Figure 3A) but also a few in tissue (Figure 3B). Using
the same antibodies, numerous NCR1+ NK cells were
detected in inflamed appendix and tonsil as positive
control tissues (Additional file 2, Page 1). Our evidence
thus indicates the presence of NK cells in small num-
bers and only in more active lesions.
NCR1 expression in astrocytes
Nevertheless, the few NK cells detected in some cases
could not account for the substantial up-regulation of
Figure 1 NCR1 expression in PBMC. (A) Representative panel indicating the gating strategy used to evaluate the expression of NCR1 on NK cells.
First, lymphocytes were gated according to SSC vs FSC, then on NK cells defined as CD56+CD3- cells. NCR1 expression was evaluated on NK cells. The
top plot shows a histogram for the isotype control and the bottom plot for the NCR1 stained cells. The expression of NCR1 was calculated as the ratio
between the MFI of NK cell NCR1 expression and the isotype control for each sample. (B) Graph shows the MFI ratios calculated as described above
for healthy controls, RRMS-untreated, RRMS-treated and PMS donors. A one-way ANOVA was conducted with Bonferroni’s correction for multiple
comparison tests and no significant difference was found (lower panel). There is a trend to lower expression in naive MS patients (MFI = 18.29 ± 4.734;
p = 0.07) compared to controls (MFI = 28.10 ± 4.2761) which may have reach baseline levels after treatment (MFI = 21.70 ± 6.313).
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mRNA identified by us. NCR1 has previously been iden-
tified as a definitive marker of NK cells [2]. This is the
first time to our knowledge that NCR1 antibodies have
been used to stain human MS brain tissue and we
detected another cell type positive expressing NCR1,
astrocytes. Numerous astrocytes positive for NCR1
could be observed in WML lesions from MS patients
(Figure 4A) with little or no expression in control white
matter (Figure 4B). In addition, tips of astrocytic pro-
cesses (end-feet) terminating on blood vessel walls were
also NCR1+ (Figure 4D).
Analysis of astrocyte staining with NCR1 antibodies of
distinct epitope specificities
To confirm the detection and specificity of expression of
a novel innate receptor on astrocytes we tested 3 other
NCR1 antibodies raised towards various domains of the
NCR1 protein on positive control tissue (tonsils) and on
human brain tissue sections. To this end we used a
mouse monoclonal raised to the recombinant full length
human NCR1 (Abcam), a goat polyclonal raised towards
the extracellular domain (R&D Systems) and a goat
polyclonal to the c-terminus (SantaCruz). All three anti-
bodies detected positive control staining of NK cells in
tonsils. Furthermore, all three antibodies stained
astrocytes in human brain tissue and more so in WML
than in controls. Expression levels differences between
disease and control were similar for all three antibodies
(Additional file 2, Page 2). We also stained tissue from
grey matter lesions in the MS brain (Figure 5A &5B)
and another neurodegenerative disease Parkinson’s dis-
ease (PD) characterised by a loss of dopaminergic neu-
rons in the substantia nigra, and presence of reactive
astrocytosis (Figure 5C &5D). We again observed the
presence of NCR1+ astrocytes.
We quantified NCR1 protein expression in white mat-
ter lesions and corroborated increases as seen at the
mRNA level. NCR1 protein levels were significantly up-
regulated (p < 0.001) in MS (4.945 ± 1.171) compared
to controls (0.801 ± 0.270; Figure 4C). NCR1 positive
staining was restricted to white matter lesions defined
by MOG and LFB staining on serial sections. Astrocytes
that were NCR1+ were restricted to WML (or the pia
Figure 2 NCR1 mRNA expression in white matter lesions. NCR1
mRNA was investigated in whole tissue RNA extract from MS white
matter lesions (WML) and control white matter. We compared levels
of NCR1 mRNA and conducted a Mann Whitney test. NCR1 mRNA
levels from MS WML were significantly (p = 0.0133) increased (3.418
± 1.368) compared to controls (0.651 ± 0.246). XPNPEP1 were used
as normaliser. Similar increased levels were confirmed with the
more commonly used normaliser GAPDH (data not shown).
Figure 3 NK cells in white matter lesions in secondary
progressive MS patients. Few NCR1+ lymphocytes were detected
in the CNS of MS patients, and only in cases showing active
demyelination (2 cases) and presenting more active than chronic
lesions. The NCR1+ cells detected were found near blood vessels (A)
but also in tissue (B). Scale bar = 10 μm.
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surface in grey matter lesions) and near blood vessels
(end-feet). In addition to the identification by their dis-
tinctive stellate morphology, we confirmed the astrocyte
phenotype by co-localising staining with the NCR1
extracellular domain antibody (Figure 4E-G) and with
the NCR1 full length antibody (Figure 4H-J) with an
antibody to the astrocytic marker, GFAP, confirming
expression of NCR1 on astrocytes.
NCR1 expression in the corpora amylacea
Antibodies raised towards the C-terminus detected posi-
tivity also in the corpora amylacea. These are spherical
Figure 4 NCR1 expression on astrocytes in WML. In the CNS, NCR1 was expressed on astrocytes and more so in WML from MS patients (A)
than in controls (B). Immunoreactivity was quantified and a significant increase (p = 0.0003) in WML (4.945 ± 1.174) compared to controls (0.801
± 0.27) was found when conducting a Mann Whitney test (C). NCR1 immunoreactivity was in general concentrated on reactive astrocytes near
blood vessels and in some instances, NCR1 positive end-feet could be distinctly observed (D). In addition to stellate morphology, the phenotype
of NCR1+ cells was confirmed using double immunofluorescence with a classical astrocyte marker, GFAP and with the mouse monoclonal to
extracellular domain (E-G) and to full length NCR1 (H-J). Scale bar = 25 μm (A & B), Scale bar = 10 μm (D).
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bodies associated with neurodegeneration and contain-
ing neuronal biowaste endocytosed and packaged by
astrocytes; this observation potentially links expression
of the NCR1 receptor on astrocytes to the specific func-
tion of endocytosis of redundant extracellular material.
The goat polyclonal to the NCR1 C-terminus detected
numerous, small, cell-like spherical bodies in WML
(Figure 6A). In Parkinson’s disease the structures
detected by this antibody were larger and more clearly
reminiscent of corpora amylacea (Figure 6B). Fluores-
cent microscopy confirmed that these structures were
un-nucleated (Figure 6D-G). The mouse monoclonal to
extracellular domain of NCR1 also detected similar
structures, though not to the same extent as the C-ter-
minus specific NCR1 antibody and only in close proxi-
mity to NCR1+ astrocytes, suggesting a role in the
process of formation of newly formed corpora amylacea
(Figure 6C and 5D).
NCR1 expression in U251 astrocytoma cells
In order to further validate de novo expression of NCR1
in astrocytes, we used in vitro analysis of human astro-
cytoma U251 cells, a well-characterised permanent
astrocytoma cell lines derived from patients with malig-
nant astrocytomas [32] and previously used in MS
studies [17]. U251 cells were grown, alongside standard
condition, in various culture conditions (cell density and
media) in order to verify whether cell stress could
induce expression of NCR1. We detected increasing
NCR1 expression with increasing cell density. This
experiment was repeated 3 times and semi-quantitative
RT-qPCR of NCR1 expression was conducted (Figure
7A). Mean signal intensity (range 0-255) was measured
from both bands and a percentage of NCR1 expression
was established from the reference gene band
(XPNPEP1). After 3 days incubation following cellular
stress we detected a de novo increase of 43% compared
to baseline (Figure 7B). We then cultured U251 cells on
chamber slides and stained for NCR1 and GFAP. NCR1
expression appeared largely cytoplasmic. We also
observed NCR1 expression on the cell surface of pro-
cesses (Figure 7C-E).
Discussion
We here show expression of a novel immunoglobulin
superfamily member, NCR1, on astrocytes which is up-
regulated in MS lesions. NCR1, which is an activating
receptor of NK cells and often considered the definitive
NK cell marker, was here used to investigate the pre-
sence of NK cells in MS brain and peripheral blood.
Figure 5 NCR1 expression in MS grey matter and in the parkinsonian brain. In the MS grey matter NCR1+ astrocytes were observed mostly
restricted to the pia surface (A) and throughout, irrespective of the presence of areas of demyelination or not. In some cases however some
intra-laminar NCR1+ astrocytes (B) were seen but very few NCR1+ astrocytes were detected in neuronal cortical layers. NCR1+ astrocytes were
detected in the PD substantia nigra (B) and also in the frontal cortex (pia surface) of the parkinsonian brain (C). Scale = 20 μm (A, C & D), Scale
= 40 μm (B).
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Detectable changes in expression of NCR1 were
restricted to the central nervous system. No significant
difference in PBMC cell surface NCR1 protein expres-
sion (or mRNA) was found between MS patients and
controls.
We demonstrated increased levels of mRNA and pro-
tein levels of NCR1 in white matter lesions from
patients with secondary progressive MS. However, we
were only rarely able to co-localize NCR1 expression to
infiltrating cells of lymphoid morphology and co-expres-
sing NK cell markers. Rather, we found the NCR1
receptor to be mainly expressed on astrocytes and on
corpora amylacea. Very few NCR1+ NK cells were found
in the MS brain parenchyma and only in those cases
showing active demyelination. Post-mortem MS brains
used in this study are progressive MS patients, so that
lesions were found at different stages of formation,
including active lesions. Our results suggest that NK
cells, being part of the innate response, may be
restricted to early lesion formation as no NCR1+ NK
cells were detected in chronic active lesions. All in all,
we show that NCR1 is not exclusive to NK cells and is
expressed on reactive astrocytes, suggesting an active
role of this molecule on astrocytes. Such a role may be
in phagocytosis and the control of redundant extracellu-
lar material. Another possible role is suggested by ana-
logy to the function of another NK cell receptor family
member, LILRB1, which is expressed by dendritic cells
Figure 6 NCR1+ Corpora amylacea. Using a goat polyclonal to the NCR1 C-terminus we detected numerous NCR1 round structures in WMLs
(A). In Parkinson’s disease tissue, near blood vessels we detected round structures bigger this time and more reminiscent of typical corpora
amylacea (B). Using fluorescence microscopy these structures contained no nucleus confirming presence of NCR1 C-terminus in the membrane
of corpora amylacea (D-G). NCR1 mouse monoclonal to extracellular domain was also able to detect only some corpora amylacea but not to the
extent as the goat polyclonal to C-terminus and only at proximity to NCR1+ astrocytes (C). Scale bar = 10 μm (A and D), scale bar = 25 μm (B
and C).
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[33]. There it appears to serve a functional role since
cell-surface ligation leads to changes in differentiation
and cytokine release [33,34].
NCR1, once considered a marker solely of NK cells, has
been identified on lymphocyte subsets other than NK
cells. Malignant CD4+ T lymphocytes from patients with
Sézary syndrome, an aggressive cutaneous T-cell lym-
phoma, express NCR1 mRNA and protein at the cell sur-
face where it appears to display a novel inhibitory function
[35]. Another study identified a small subset of NCR1+
natural killer T cells (NKT) cells that in the presence of
interleukin-15 (IL-15) are susceptible to leukemic transfor-
mation and become a functionally distinct subset [36].
NK cells are classified as part of a family of haemato-
poietic effectors cells referred to as innate lymphoid
cells (ILCs). These ILCs have a principal protective
function in response to infectious agents. Other func-
tions attributed to these cells are assistance in lymphoid
tissue formation, in tissue remodelling after injury and
in homeostasis of tissue stromal cells [37]. Astrocytes
are able to produce cytokines such as IL-1b, TGF-b, IL-
4, IL-6, IL-10, IL-12, IL-17, IL-23 [38] and more
recently IL-15 [39], altering the inflammatory cytokine
milieu for adaptive immunity. Their role thus extends
beyond support for neurones to an active role as regula-
tors in CNS immunity. The current view on astrocyte
origin suggests that they derive from radial glia emer-
ging from the neural crest [40]. This is thus a comple-
tely distinct lineage to the ILCs, here found to express
NCR1. Nevertheless other IgSF members have been
found on astrocytes. In 2003, a Japanese team isolated a
novel dual Ig domain (V-type) immunoglobulin, limitrin
(also known as matrix-remodelling associated 8), on
astrocytic end-feet and based on this evidence suggested
that limitrin is physically and functionally associated
with the blood-brain barrier [41]. Many members of the
immunoglobin superfamily mediate either homophilic or
heterophilic cell adhesion interactions, and serve as
receptors mediating cell to cell or cell to extracellular
matrix interactions [42]. One of the most prevalent
immunoglobulin cell adhesion molecule (IgCAM) in the
vertebrate nervous system is N-CAM1 (neural cell adhe-
sion molecule 1; CD56). Homophilic interactions
between N-CAM molecules on adjacent cells are
Figure 7 De novo expression of NCR1 mRNA in human U251 astrocytoma cells after stress. The human U251 astrocytoma cell line was
used to look for de novo expression of NCR1 in astrocytes. Expression of NCR1 mRNA was detected when cells were cultures at a concentration
of 2 × 106/well (A). No reverse transcription samples were negative, confirming that the bands were from de novo NCR1 mRNA production after
stress and not from genomic DNA. Semi-quantitative analysis of NCR1 expression showed a 43% increase in NCR1 expression after 3 days of
culture. Double immunofluorescence (GFAP-NCR1) confirmed presence of NCR1 protein on the human U251 astrocytoma cell line (C-E).
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thought to bind cells together [43]. CD56 is widely used
as a marker defining NK cells [25] though expression is
also found on neurones, oligodendrocytes and astro-
cytes. NCAM1 or its polysialylated form (PSA-NCAM),
was shown to be expressed on demyelinated neurones
[44] and widespread distribution in the CNS has been
extensively documented [45]. Three main isoforms with
molecular weights of 120, 140, and 180 kDa are derived
from the single gene. NCAM-120 is the predominant
form expressed by mature oligodendrocytes [46]. PSA-
NCAM was colocalised with reactive astrocytes in the
rat [47] and in humans [48]. Thus astrocytes and NK
cells have not just one receptor in common but, based
on our evidence, a second receptor, NCR1.
In our study, staining of the NCR1 C-terminus was
mostly localised to the corpora amylacea. Corpora amy-
lacea are globular basophilic bodies between 10 to 50
μm in diameter, which are believed to develop in astro-
cytic processes and to be associated with neurodegen-
eration [49]. These round inclusions appear with normal
aging after the age 40 and are rarely observed in the
adolescent brain [50]. Mostly observed in Alzheimer’s
disease [51] and in PD [52], there are also reports of
prevalence of these inclusions in MS. For instance, pro-
teomic analysis from MS patients’ lesions confirms that
these bodies contained mostly neuronal aggregates with
highly polymerised cytoskeletal material [53]. Whether
NCR1 is involved in the formation of these inclusions
remains to be fully determined.
In order to further validate our findings, we analysed
NCR1 expression in U251 cells. This confirmed expres-
sion of NCR1 at the mRNA and protein level in cells
grown with serum deprivation or at high density.
Conclusions
Taken together, the data presented here indicate de novo
expression of NCR1 receptor on astrocytes in MS white
matter lesions, in addition to the more marginal popula-
tion of NCR1+ NK cells. Other adhesion molecules such
as CD56 are also expressed by astrocytes, along with
cytokines, supporting a role of astrocytes in innate
immune activation in the CNS in MS. It remains to be
determined whether NCR1 on astrocytes can signal or
function as co-receptor. We favour the possibility that it
may be acting as an innate receptor for local stress in
the form of altered carbohydrate moieties. In any case,
our results argue for NCR1 as a potential CNS tissue
marker of neurodegenerative disease.
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